SHIFTBIO INC.

SHIFTBIO is sending warm wishes to everyone for a Merry Christmas and a Happy New Year! To mark the conclusion of 2024, we hosted a farewell gathering and are now gearing up for an exciting new chapter in 2025. We extend our heartfelt gratitude to everyone who has supported us with unwavering trust and dedication. In the new year, SHIFTBIO will continue to strive for excellence and achieve even greater progress. #SHIFTBIO #Biotech #Farewell #Yearend #Christmas #NNP #Startup #Therapeutic #Development #Platform #Technology

SHIFTBIO INC. was recognized and awarded as an outstanding “Global Collaboration Company” at the ‘2024 Global Corporate Collaboration Program – Achievement Sharing and Technology Forum’ held on December 9th. Gi-Hoon, CEO of SHIFTBIO INC., presented the company's achievements to other corporate attendees. We extend our sincere gratitude to everyone who has trusted and supported us. In 2025, we will continue to strive and work even harder to deliver outstanding results and meet everyone’s expectations. #SHIFTBIO #EV #Based #Therapeutic #Development #NNP #BIotech #Startup #Platform #Technology

We were delighted to welcome the RoosterBio Inc. team to our SHIFTBIO Seoul office! It was a meaningful discussion where we not only strengthened our partnership but also explored ideas for upcoming projects. We look forward to collaborating closely and driving impactful results together in the near future.

This September, SHIFTBIO was honored to once again participate in the prestigious Exosome-Based Therapeutic Development Summit held in Boston. For the third consecutive year, SHIFTBIO’s co-founder and co-CEO, Gihoon Nam, delivered a compelling presentation highlighting our groundbreaking Natural Drug Delivery Platform and our vision for the future of drug delivery. The summit provided an invaluable opportunity for us to engage with cutting-edge technologies and expand our professional network within the global community. These interactions are crucial as we continue to lead the paradigm shift in global drug development. We extend our heartfelt thanks to all the organizers and participants for another insightful event. SHIFTBIO is committed to seizing every opportunity to advance and innovate within the industry. #SHIFTBIO #Exosome #Based #Therapeutic #Development #Summit #Biotech #Startup #Natural #Nanoparticle #Drug #Delivery #Platform #DDS

SHIFTBIO INC. is proud to announce that we have been invited to the ‘Korea Conference 2024’ for the third consecutive year. On August 23rd in Los Angeles, global business leaders, including Tom Lawrence, President of the Eden Club, and Silicon Valley venture capitalists, gathered to express their strong interest in promising Korean startups, including SHIFTBIO INC. Building on our achievement of securing first place in the IR presentation at the Korea Conference 2023, we proudly shared our significant accomplishments over the past year. SHIFTBIO INC. also unveiled our strategic plans for global market expansion and engaged proactively with investors to foster new opportunities. We remain committed to excellence, continuing to drive forward with dedicated research and innovation. Thank you all for your continued support. #SHIFTBIO #KoreaConference2024 #Biotech #Pharmaceutical #Natural #Nanoparticle #New #DDS #Platform #Technology #Therapeutic #Research #Development

We are delighted to share the preprint of our second program, HIF1α-NNP.   This manuscript showcases in vivo macrophage reprogramming by NNP (natural nanoparticle) mediated delivery of transcription factor HIF1α for enhanced trained immunity. Delivering HIF1a to macrophages during severe inflammatory conditions promoted the differentiation of Nr1h3-dependent pro-efferocytic and Cebpb-dependent pro-survival MoMFs. Pro-efferocytic MoMFs eliminate damaged cells, and pro-survival MoMFs withstand inflammatory conditions and trigger innate memory responses. This study highlights that NNP-mediated transcription factor delivery for in vivo macrophage reprogramming could be a promising therapeutic option for managing inflammatory diseases.   The outstanding members of KIST led this work in collaboration with SHIFTBIO.   Check out the full preprint here: https://lnkd.in/gTx7um7j #SHIFTBIO #Preprint #Second #Program #HIF1a #NNP #Biotech #Startup #Pharmaceutical #Natural #Nanoparticle #New #DDS #Platform #Therapeutic #Research #Development

SHIFTBIO INC. was honored as the Top Poster at the 'EASL Congress 2024' held in Milan, Italy, solidifying its global presence. Our poster on the mechanism and efficacy of SIRP-EV in treating Acute Liver Failure (ALF) garnered significant resonance and questions during the conference. We extend our heartfelt thanks to everyone who has supported us, and we are committed to delivering even more achievements in the future. #SHIFTBIO #EASL #2024 #Milan #Italy #Top #Poster #Biotech #Startup #Pharmaceutical #First #Program #EV #Research #Development #Platform #Technology

SHIFTBIO INC. participated in the prestigious International Society for Cell & Gene Therapy (ISCT) 2024 conference in Vancouver, Canada. Gi-Hoon Nam, the CEO of SHIFTBIO INC., attended as an invited speaker and delivered both a session and a poster presentation, significantly expanding our network with distinguished global researchers. Through these presentations, SHIFTBIO introduced our proprietary NSM platform technology and our first pipeline, SBI-102. Additionally, we've attended various sessions to gain insights into global CGT market trends and engaged in productive meetings to discuss potential collaborative research opportunities. SHIFTBIO remains committed to unwavering progress and innovation. Please stay tuned for our upcoming developments and achievements! #SHIFTBIO #ISCT #2024 #Vancouver #CGT #Speaker #Biotech #Startup #Pharmaceutical #NSM #SBI102 #NNP #Natural #Nanoparticle #New #Modality #Platform #Technology #Research #Development

We are thrilled to announce that Dr. Dolores Di Vizio, a world-class scientist in circulating extracellular vesicles, has joined SHIFTBIO INC’s Scientific Advisory Board (SAB). Dr. Di Vizio is the co-leader of the Cancer Biology Program at Cedars-Sinai Cancer Institute and a senior advisor of the International Society of Extracellular Vesicles (ISEV). SHIFTBIO's SAB now includes Dr. Dolores Di Vizio, Dr. Thomas M. Roberts, and Dr. Kenneth W. Witwer. Through this collaboration, SHIFTBIO is strengthening its research foundation and expanding its expertise. Stay tuned for updates on our progress and future developments! #SHIFTBIO #SAB #Scientific #Advisory #Board #Biotech #Startup #Pharmaceutical #EV #New #Modality

We are delighted to share the preprint of our first program, SIRP-NNP. This manuscript showcases the exceptional therapeutic efficacy of SIRP-NNP in treating acute liver failure, along with our rigorous manufacturing process. SIRP-NNP demonstrates a dual-mode action therapeutic approach to this rare disease, which currently lacks effective treatment options. The study further highlights our comprehensive NNP manufacturing process, from engineering primary cells to purifying NNPs, ensuring large-scale scalability, high yield, and high purity. This work was led by the outstanding members of SHIFTBIO INC., in collaboration with RoosterBio. Check out the full preprint here:  https://lnkd.in/gs2XyptB #SHIFTBIO #Preprint #Lead #Program #SIRP #NNP #Biotech #Startup #Pharmaceutical #Natural #Nanoparticle #New #Modality #Platform #Therapeutic #Research #Development